Investors
Investor Relations Contact
investorrelations@transgene.com
Media Relations France
Citigate Dewe Rogerson & Grayling
Marie Frocrain/Olivier Bricaud
Phone: +33 (0)6 6 63 03 84 91
transgeneFR@citigatedewerogerson.com
Media Relations International

- November 9, 2026Transgene Reports Continued Clinical Progress and Q3 2026 Financial Update
- November 5, 2026First Patient Dosed in Phase 1 Trial Evaluating Transgene’s and BioInvent’s BT-001 in Patients with Rectal Cancer
- November 3, 2026Transgene to Present Preclinical Data on Novel Oncolytic Virus at SITC 2026 Supporting its Potential for Systemic Delivery
- October 5, 2026Transgene Will Present a Poster on Preclinical Data from a Novel Oncolytic Virus at SITC 2026
- October 1, 2026Transgene To Participate in Investor Access
- September 24, 2026Transgene Extends its myvac® Platform, Further Establishing its Position as a Key Player in the Rapidly Emerging Individualized Cancer Immunotherapy Field
- September 8, 2026Transgene and ProBioGen Expand Strategic Partnership with Additional License Agreement for AGE1.CR.pIX Cell Line
- September 2, 2026Transgene and NEC Report 100% Three-Year Disease-Free Survival with TG4050 and Publish Phase 1 Results in Nature Communications
- June 25, 2026Transgene to Present Preclinical Data Demonstrating Robust Protection Against Mpox with its Novel Scalable Cell Line-Derived MVA Vaccine Candidate (TG MVA(TM)) at WCID 2026
- June 22, 2026Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine
See all press releases
Investor events
Financial calendar
- November 9, 2026Third Quarter 2026 Financial Results
- April 29, 2026First Half 2026 Financial Results
- March 24, 20262025 Full-year Results
General
| Stock Market | Euronext Paris – Eurolist (compartiment B) |
| Reuters / Bloomberg | TRNG.PA / TNG.FP |
| ISIN Code | FR0005175080 |
| Total number of shares outstanding | 274,186,709 |
| Initial Public Offering (IPO) | March 26, 1998 |
| Local Sector Index | Next Biotech |
| Financial Year Ends | December 31 |
| Company | Analyst | Phone | |
|---|---|---|---|
| Kempen | Chiara Montironi | c.montironi@vanlanschotkempen.com | + 31 610552719 |
| Intron Health | Naresh Chouhan | naresh@intronhealthresearch.com | +44 207 375 9143 |
| Invest Securities | Jamila El Bougrini | jelbougrini@invest-securities.com | +33 (0)1 44 88 88 09 |
| Oddo BHF | Martial Descoutures | martial.descoutures@oddo-bhf.com | +33 (0)1 44 51 85 00 |
Any opinions, forecasts, estimates, projections or predictions regarding Transgene’s performance made by the analysts are theirs alone and do not necessarily represent the opinions, forecasts, estimates, projections or predictions of Transgene or its management. By providing the names of the analysts or certain information from them, Transgene does not imply its endorsement of or concurrence with their reports, conclusions or recommendations. Transgene assumes no liability for the accuracy of such information and undertakes no obligation to update it.
Annual General Meeting of May 22, 2026
2026 ORDINARY AND EXTRAORDINARY MEETING
Location: TRANSGENE
400 boulevard Gonthier d’Andernach – Parc d’Innovation 67400 ILLKIRCH-GRAFFENSTADEN – FRANCE
Date and Time: May 22, 2026 at 11 am CET
Documents
- Notice of 2026 Meeting
- Notice of the 2026 General Shareholder’s Meeting (BALO)
- French BALO publication, including resolutions
- French notice of AGM
- Presentation on draft resolutions
- Ballot paper (in French)
- Information regarding the total number of the outstanding shares and voting rights of the Company (Article R. 225-73-1 French Commercial code)
- 2025 Universal Registration Document
- Information provided in accordance with Article R.225-83 of the French Commercial Code
- Results of the vote (in French)
As pioneers in viral genome engineering, we have one ambition: To create innovative treatments to fight cancers.


